C4 Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
The following table describes, for the three months ended September 30, 2026, each trading arrangement for the purchase or sale of Company securities adopted, modified orterminated by our directors and officers that is either (1) a contract, instruction, or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement” or (2) a “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement (Nature of Trading Arrangement) | Duration of Trading Arrangement(1) | Aggregate Number of Securities Pursuant to Trading Arrangement |
|---|---|---|---|---|
| Kendra Adams (Chief Financial Officer, Head of Corporate Affairs) | Adoption (August 13, 2026) | Rule 10b5-1 trading arrangement (sale) | 9/30/2027 | 156,173, plus an indeterminable number(2) |
(1) Except as otherwise indicated, the trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all sales, (b) the date listed in this column or (c) the date the trading arrangement is otherwise terminated.
(2) Ms. Adams's Rule 10b5-1 Trading Plan provides for the sale of up to (i) 156,173 shares of common stock and (ii) an indeterminable number of shares of common stock from the settlement of RSUs. The number of shares of common stock in clause (ii) is indeterminable because the number will vary based on the extent to which vesting conditions are satisfied, the market price of the Company's common stock at the time of settlement and the number of shares that would otherwise be issuable on each settlement date of a covered RSU that are sold or withheld in an amount sufficient to satisfy the applicable tax withholding obligations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.